# US 5,858,669 A · Beclin, a novel bcl-2 interacting gene near BRCA1 on chromosome 17q21 and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,669 A
- Document ID: US5858669A
- Status: Granted
- Kind: A
- Application number: 08/712,939
- Filed: 1996-09-13
- Granted: 1999-01-12
- Earliest claimed: 1996-09-13
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Beth Cindy Levine
- Web page: https://patentgrep.com/patent/US5858669A

## CPC

- C07K 14/82: Translation products from oncogenes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/156: Polymorphic or mutational markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides for an isolated nucleic acid which encodes a wildtype human Beclin and a mutant human Beclin. This invention also provides a vector containing the isolated nucleic acid which encodes a wildtype human Beclin. This invention also provides for a method of producing a wildtype human Beclin. This invention also provides for a purified, wildtype human Beclin. This invention also provides for a method for determining whether a subject has a predisposition for cancer. This invention also provides a method for determining whether a subject has cancer. This invention also provides for a method for inhibiting cell proliferation in cells unable to regulate themselves. This invention also provides for a method for treating a subject who has cancer. This invention also provides a pharmaceutical composition composed of the wildtype human Beclin. This invention also provides a method for detecting a mutant human Beclin in a subject. This invention also provides a method for treating a subject unable to control apoptosis in the cells of the subject.

## Claims

### Claim 1

A method for identifying a subject with a predisposition for cancer, comprising:
a. obtaining a nucleic acid sample from the subject; and
b. determining whether the nucleic acid which in wildtype form encodes human Beclin is encoding a polypeptide having no cellular proliferation inhibition activity or reduced cellular proliferation inhibition activity, wherein no cellular proliferation inhibition activity or reduced cellular proliferation inhibition activity indicates a predisposition to cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the determining of step b comprises: determining whether the nucleic acid which in wildtype form encodes a human Beclin contains a premature stop codon, wherein a premature stop codon indicates a predisposition to cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nucleic acid sample in step (a) comprises mRNA.

### Claim 4 (depends on 2)

The method of claim 2, wherein the nucleic acid sample in step (a) comprises mRNA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the determining of step (b) comprises:
i. producing a protein from the nucleic acid sample of step (a); and
ii. comparing the protein of step (i) with wildtype human Beclin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the determining of step (b) comprises:
i. producing a protein from the nucleic acid sample of step (a); and
ii. assessing the protein of step (i) for its ability to restore cellular proliferation inhibition activity to a cell having no Beclin or reduced levels of Beclin.

### Claim 7

A method of detecting a nucleic acid encoding a mutant human beclin comprising:
(a) hybridizing the nucleic acid with a probe consisting of a nucleic acid which encodes SEQ ID NO 1,
(b) isolating the nucleic acid obtained by hybridization,
(c) determining the nucleotide sequence of the isolated nucleic acid, and
(d) comparing the nucleotide sequence of the isolated nucleic acid with a nucleotide sequence which encodes SEQ ID NO 1 in order to identify a mutant human beclin.

### Claim 8

A method of detecting a nucleic acid encoding a mutant human beclin comprising:
(a) hybridizing the nucleic acid with a probe consisting of the nucleotide sequence of SEQ ID NO 2,
(b) isolating the nucleic acid obtained by hybridization,
(c) determining the nucleotide sequence of the isolated nucleic acid, and
(d) comparing the nucleotide sequence of the isolated nucleic acid with the nucleotide sequence of SEQ ID NO 2 in order to identify a mutant human beclin.
